Abiraterone acetate soft capsule and preparation method thereof

Nanomilk is formed by components such as caprylic caprylate mono-diglyceride in abiraterone acetate soft capsule preparation, which improves its bioavailability, solves the problems of low solubility and osmotic pressure difference, and reduces food influence and inter-individual variation and ensures the stability and ease of production of the preparation.

CN118948790APending Publication Date: 2024-11-15HANGZHOU HEZE PHARMA TECH CO LTD +1
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202410429215.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2021-07-22
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The low solubility and osmotic pressure difference of abiraterone acetate lead to low oral bioavailability, and food affects its absorption. The prior art is difficult to effectively improve its bioavailability and reduce inter-individual variability.

Method used

Abiraterone acetate soft capsule preparation, the contents include abiraterone acetate, mono-diglyceride caprylate, Tween 80, Sipan 80 and butyl hydroxyanisole to form O/W nanoemulsion and increase intestinal tract Penetration of epithelial cells improves bioavailability and avoids precipitation of drugs in long-term storage through stable composition.

Benefits of technology

It significantly improves the oral bioavailability of abiraterone acetate, reduces food impact, reduces inter-individual variability, and ensures the long-term stability of the preparation and the simplicity of commercial production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

The invention discloses an abiraterone acetate soft capsule and a preparation method thereof. The soft capsule is composed of a content and a capsule shell, wherein the content comprises abiraterone acetate, caprylic / capric acid mono / diglyceride, Tween 80, Span 80 and butylated hydroxyanisole; the capsule shell is made of soft capsule materials and comprises gelatin, water, glycerol and a sorbitol and sorbitan solution, and the ratio of the gelatin to the water to the glycerol to the sorbitol and sorbitan solution is 1: 0.74: 0.35: 0.35. After the abiraterone acetate soft capsule provided by the invention is orally taken on an empty stomach, compared with an original research medicine Zytiga (the specification is 250mg), the step of dissolving out the original research medicine Zytiga on the digestive tract is not needed, the oral bioavailability is improved to 12.5 times, the variability among individuals is low, and the phenomenon that the abiraterone exposure quantity is obviously increased due to postprandial administration of the original research medicine Zytiga is eliminated.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of pharmaceutical preparations, and particularly relates to an abiraterone acetate soft capsule and a preparation method thereof. Background Art

[0002] Abiraterone Acetate is a white to off-white, non-hygroscopic crystalline powder. Abiraterone Acetate is a prodrug of abiraterone, a selective irreversible inhibitor of 17α-hydroxylase / C17,20-lyase (CYP17). The enzyme is expressed in testicular and adrenal tissues and catalyzes the conversion of pregnenolone and progesterone to testosterone precursors, DHEA and androstenedione, respectively, through 17α hydroxylation and cleavage of the C17,20 bond. Abiraterone can inhibit the activity of CYP17 to prevent testosterone synthesis in the testes, adrenal glands and tumors. Prostate cancer is an androgen-dependent disease, and testosterone inhibition is a key pharmacological tool in controlling the development of prostate cancer. The chemical structure of abiraterone acetate is shown in Formula 1 below:

[0003]

[0004] Abiraterone acetate is a lipophilic compound with an octanol-water partition coefficient of 5.12 (LogP) and a pKa of aromatic nitrogen of 5.19. It is almost insoluble in water (0.01 mg / ml) and has an osmotic pressure difference. It is a BCS Class IV drug and has extremely low bioavailability when absorbed orally.

[0005] The original drug Zytiga Abiraterone Acetate Tablets (specification 250mg) were developed by Janssen-Cilag International NV of Belgium. Inactive ingredients include: colloidal titanium dioxide, cross-linked carboxymethylcellulose sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose, povidone and sodium lauryl sulfate. It is approved in the United States for use in combination with prednisone to treat metastatic castration-resistant prostate cancer (mCRPC). The oral bioavailability of the original drug Zytiga is very low (less than 10%). The daily dose is as high as 1000mg, but only less than 10% of the drug can exert its efficacy.

[0006] The prescription information of the original drug Zytiga states that it must be taken on an empty stomach and that food should not be consumed within at least 2 hours before and at least 1 hour after taking the drug, indicating that food has a significant effect on the absorption of abiraterone acetate, and commercially available preparations require that it can only be taken during a specific time period before meals. The Zytiga instructions emphasize that when abiraterone acetate is given with food, the systemic exposure of abiraterone increases. Specifically, when abiraterone acetate is given with a low-fat meal (7% fat, 300 calories), the Cmax and AUC of abiraterone are significantly higher than those of abiraterone acetate alone. 0-∞When abiraterone acetate was given with a high-fat meal (57% fat, 825 calories), the Cmax and AUC of abiraterone were increased by approximately 7-fold and 5-fold, respectively. 0-∞ The increase was about 17 times and 10 times respectively. Although abiraterone acetate is effective in the oral treatment of advanced prostate cancer, its low solubility and osmotic pressure difference have caused serious problems in the development of preparations.

[0007] Patent CN106687112A provides a modified abiraterone acetate preparation, which controls the particle size of the raw material abiraterone acetate to make a unit dosage form of abiraterone, wherein the unit dosage form of 500 mg is bioequivalent to the 1000 mg dose of Zytiga in healthy male subjects in the fasting state, and the bioavailability is increased by 1 times. Although the dosage of the preparation is reduced by 500 mg, the abiraterone acetate is only crushed to control the particle size within a smaller range to facilitate dissolution and absorption, and the permeability of abiraterone acetate to gastrointestinal epithelial cells is not increased. The oral bioavailability is still very low, and the specific surface area of ​​abiraterone acetate is too large after crushing, which increases the risk of oxidation of abiraterone acetate.

[0008] Patent CN102961358B relates to an abiraterone acetate liquid capsule, comprising a capsule shell and contents, characterized in that the contents are composed of abiraterone acetate, solvent, monoglyceride and antioxidant: the solvent is selected from: glycerol fatty acid diester, glycerol fatty acid triester, 1,2-propylene glycol and a mixture thereof. However, the propylene glycol contained in the liquid capsule contents can volatilize from the contents during storage, causing the propylene glycol content in the contents to be severely reduced, resulting in the precipitation of abiraterone, which may cause major quality problems.

[0009] Patent document CN107278152A relates to an abiraterone acetate complex, a preparation method thereof and a pharmaceutical composition containing them, which comprises 5-40% by weight of abiraterone acetate, 5-80% by weight of a polyethylene caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, and 0.1-50% by weight of sodium deoxycholate. The complex can reduce the effect of food and abandon the requirement of taking the drug on an empty stomach, and can increase the oral bioavailability by up to 5 times, but the preparation process of the complex preparation is complicated.

[0010] Patent document CN110538150A The present invention relates to the field of pharmaceutical preparation technology, and in particular to a pharmaceutical composition containing abiraterone acetate, and a preparation method and application thereof. The pharmaceutical composition comprises: an active ingredient: abiraterone acetate; excipients: at least one oil phase, at least one emulsifier, and at least one emulsifier. After oral administration, the pharmaceutical composition provided by the present invention spontaneously disperses into an O / W type nanoemulsion under gastrointestinal peristalsis when it encounters the gastrointestinal tract. The formed nanoemulsion has a small particle size, which increases the permeability of intestinal epithelial cells and can significantly improve the bioavailability of the drug. Compared with microemulsion, the self-emulsifying solution has higher stability and can meet the requirements of long-term storage. The pharmaceutical composition of the present invention has a stable content. Compared with the original drug Zytiga, the difference between before and after meals is significantly reduced; the pharmaceutical composition can also be further prepared into capsules, and the capsules have stable properties. However, the co-emulsifiers ethanol, propylene glycol, etc. used in the patent can be exerted from the contents during storage, resulting in a serious reduction in the content of ethanol or propylene glycol in the contents, which may cause abiraterone to precipitate during long-term storage.

[0011] In summary, it can be seen that abiraterone acetate has the characteristics of low solubility and osmotic pressure difference. By crushing abiraterone acetate and controlling the particle size within a smaller range, the problem of poor oral bioavailability has not been significantly solved. Preparing abiraterone acetate into liquid capsules can theoretically significantly improve the oral bioavailability of abiraterone acetate and eliminate the effect of food. However, the contents of the liquid capsules are composed of propylene glycol or ethanol, which is volatile and may cause abiraterone to precipitate during long-term storage. Summary of the invention

[0012] In view of the above problems in the prior art, the object of the present invention is to provide a soft capsule preparation that can significantly improve the oral bioavailability of abiraterone acetate, reduce inter-individual variability, and eliminate the effect of food.

[0013] The technical solution provided by the present invention is:

[0014] An abiraterone acetate soft capsule comprises contents and a capsule shell, wherein the contents comprise active ingredients of abiraterone acetate, caprylic and capric mono- and di-glycerides, Tween 80, Span 80 and butylated hydroxyanisole.

[0015] Preferably, the total volume of the contents is such that the concentration of abiraterone acetate is between 60-100 mg / ml;

[0016] and / or

[0017] The mass of the abiraterone acetate accounts for 6-10% of the total mass of the drug content.

[0018] Preferably, the mass of the caprylic / capric mono- and di-glycerides accounts for 60-77% of the total mass of the drug content.

[0019] More preferably, the contents include: the mass of the abiraterone acetate accounts for 6-10% of the total mass of the drug contents, and the mass of the caprylic and capric mono- and di-glycerides accounts for 60-77% of the total mass of the drug contents.

[0020] Preferably, the mass of Tween 80 accounts for 6-15% of the total mass of the drug content.

[0021] Preferably, the mass of the Span 80 accounts for 7-19% of the total mass of the drug content.

[0022] More preferably, the mass of the abiraterone acetate accounts for 6-10% of the total mass of the drug contents, the mass of the caprylic capric acid mono- and diglycerides accounts for 60-77% of the total mass of the drug contents, the mass of the Tween 80 accounts for 6-15% of the total mass of the drug contents, and the mass of the Span 80 accounts for 7-19% of the total mass of the drug contents.

[0023] Preferably, the mass of the butylated hydroxyanisole accounts for 0.01%-0.1% of the total mass of the drug content.

[0024] Preferably, the capsule shell is made of soft capsule material, and its composition includes: gelatin, water, glycerin, sorbitol sorbitan solution MDF85, and the proportion of each component is 1:0.74:0.35:0.35.

[0025] More preferably, the contents include: the mass of the abiraterone acetate accounts for 6-10% of the total mass of the drug contents, the mass of the caprylic and capric mono- and diglycerides accounts for 60-77% of the total mass of the drug contents, the mass of the Tween 80 accounts for 6-15% of the total mass of the drug contents, the mass of the Span 80 accounts for 7-19% of the total mass of the drug contents, and the mass of the butylated hydroxyanisole accounts for 0.01%-0.1% of the total mass of the drug contents.

[0026] More preferably, an abiraterone acetate soft capsule comprises contents and a capsule shell, wherein the contents comprise: the mass of the abiraterone acetate accounts for 6-10% of the total mass of the drug contents, the mass of the caprylic capric acid mono- and diglycerides accounts for 60-77% of the total mass of the drug contents, the mass of the Tween 80 accounts for 6-15% of the total mass of the drug contents, the mass of the Span 80 accounts for 7-19% of the total mass of the drug contents, and the mass of the butylated hydroxyanisole accounts for 0.01%-0.1% of the total mass of the drug contents; the capsule shell is composed of a soft capsule material, and its composition comprises: gelatin, water, glycerin, and sorbitol sorbitan solution (MDF85), and the ratio of each component is 1:0.74:0.35:0.35.

[0027] The invention also discloses a method for preparing the above-mentioned abiraterone acetate soft capsule, which comprises: 1) gelling: adding a prescribed amount of glycerol, sorbitol, sorbitan and water into a gelling barrel, starting stirring, waiting for the temperature in the barrel to rise to 75-80°C, after the materials are evenly mixed, adding a prescribed amount of gelatin, and simultaneously evacuating to -0.05--0.06MPa, maintaining negative pressure stirring for 25-35min, opening a top-filling respirator until the vacuum disappears, keeping warm at 55-60°C for degassing, and setting aside; 2) preparing contents: dissolving abiraterone acetate in a mixed solution of caprylic and capric mono- and diglycerides, Tween 80, Span 80 and an antioxidant heated to 50°C, stirring evenly, and setting aside; 3) pilling: using a soft capsule machine for pilling; and 4) drying.

[0028] Wherein, as the above-mentioned abiraterone soft capsule, calculated as abiraterone acetate, a single oral dose is 36-60 mg.

[0029] The present invention also discloses the use of abiraterone acetate soft capsule in the preparation of a pharmaceutical preparation;

[0030] Preferably, the use in preparing a pharmaceutical preparation for treating prostate cancer;

[0031] More preferably, the prostate cancer is one or both of metastatic castration-resistant prostate cancer and metastatic high-risk castration-sensitive prostate cancer.

[0032] The excipients of the contents provided by the present invention can be used as carriers of hydrophobic, poorly soluble or easily hydrolyzed drugs. After oral administration, the contents are spontaneously dispersed under gastrointestinal peristalsis to form O / W type emulsion droplets, which increase the permeability of intestinal epithelial cells, increase drug dissolution, promote absorption, and significantly improve drug bioavailability. The contents can be directly loaded into soft capsules to meet the requirements of long-term stable storage.

[0033] The soft capsule containing abiraterone acetate of the present invention has at least one of the following properties:

[0034] 1) Abiraterone acetate is made into soft capsules to increase drug dissolution, and can be mixed with water to quickly and spontaneously form emulsion droplets with high clarity and stable properties;

[0035] 2) When stored at room temperature, the quality is stable and controllable, and within 6 months of accelerated storage, the quality is better than Example 1 of Patent CN110538150A;

[0036] 3) The content formula of patent CN110538150A contains propylene glycol and ethanol. As the storage time increases, propylene glycol and ethanol may penetrate the capsule shell and evaporate, reducing the solubility of the drug and causing precipitation of abiraterone acetate. This patent will successfully avoid this problem and make it easier to store;

[0037] 4) Compared with the original drug Zytiga, the difference between pre-meal and post-meal was significantly reduced, reducing the variability between individuals;

[0038] 5) Compared with the original drug Zytiga, after oral administration of abiraterone acetate soft capsules on an empty stomach, there is no need to go through the dissolution step of the original drug Zytiga in the digestive tract, and the oral bioavailability is increased to 12.5 times;

[0039] 6) All ingredients in the prescription are conventional excipients, which are easily available, and the preparation process is simple, the product quality is stable, and it is easy to commercialize.

[0040] Determination of solvent

[0041] Abiraterone soft capsule preparations are composed of the contents of abiraterone soft capsules and the soft capsule shell. The content prescription needs to be studied at the same time. First, the solvent of the self-made preparation is determined. This experiment studies the dissolution of the raw materials in the contents of abiraterone soft capsules in various solvents. In this experiment, 10g of purified water, ethanol, castor oil, capmulMCM (caprylic acid capric acid mono- and diglycerides), hydrogenated castor oil, and medium-chain triglycerides were taken respectively to study the dissolution of abiraterone acetate (API) in these solvents, as shown in Table 1 for details.

[0042] Table 1. Dissolution of Abiraterone Acetate

[0043]

[0044] As shown in Table 1, ① Abiraterone acetate has high solubility in ethanol, castor oil, caprylic and capric mono- and di-glycerides, but when ethanol is used as a solvent, a large amount of crystals are precipitated after being left at room temperature for 24 hours; it is only soluble in medium-chain triglycerides by 3% (25°C), and is almost insoluble in hydrogenated castor oil and purified water. ② Generally speaking, if the self-microemulsifying drug delivery system is finally made into soft capsules or hard capsules, and contains ethanol and other volatile components, these substances may penetrate the capsule shell, reduce the solubility of the drug, and cause the precipitation of lipophilic drugs. For example, if the self-made preparation uses ethanol as the solvent, because ethanol is easy to seep out and volatilize from the capsule shell, the proportion of ethanol in the content will be seriously reduced during the preparation and storage process, which may cause the drug to crystallize out; ③ By comparing the dissolution of abiraterone acetate in castor oil and caprylic capric acid mono- and diglycerides, it can be seen that abiraterone acetate is more soluble in caprylic capric acid mono- and diglycerides, and caprylic capric acid mono- and diglycerides themselves have a certain emulsifying effect, which is conducive to the spontaneous dispersion of the self-made preparation under gastrointestinal peristalsis to form O / W type emulsion droplets. Therefore, the preparation uses caprylic capric acid mono- and diglycerides as the solvent of the self-made preparation.

[0045] Determination of surfactant

[0046] In order to make the self-made preparations disperse spontaneously to form O / W type emulsion droplets when encountering gastrointestinal fluid under gastrointestinal peristalsis after oral administration, the surfactants are mostly non-ionic surfactants with high hydrophilic-lipophilic balance (HLB) values ​​(generally 9-20), low toxicity, relatively stable in solution, not affected by strong dielectrics, inorganic salts, acids and alkalis, good compatibility with other types of surfactants, small hemolytic effect, compatible with most drugs, and can cause reversible changes in gastrointestinal wall permeability. At the same time, the selection of surfactants should consider matching with the oil phase. In this experiment, surfactants such as polyoxyethylene castor oil (EL-40), Span 80, Tween 80 and polyethylene glycol-15 hydroxystearate (Solutol) were selected, and two or three of these surfactants were organically combined. It was unexpectedly found that when polyoxyethylene castor oil: Tween 80: Span 80 = 1:1:0.25 and Tween 80: Span 80 = 1:1.25, the emulsification effect was the best, and slight shaking formed emulsion droplets with blue opalescence, and they could exist stably. See Table 2 for details.

[0047] Table 2. Selection of surfactants

[0048]

[0049] The composition of these two surfactants is now used to prepare soft capsules to investigate their effects on product quality.

[0050] Table 3. Effect of surfactants on product quality (40℃±2℃ / 75%RH±5%RH)

[0051]

[0052]

[0053] It can be seen from Table 3 that different surfactant compositions have different effects on product quality. When Tween 80: Span 80 = 1:1.25, the product quality meets the requirements, and when accelerated for 3 months, its total impurities are significantly lower than that of prescription 2.

[0054] In summary, the surfactant composition of the self-developed formulation is Span 80 and Tween 80, and on this basis, the dosage of each surfactant is further optimized, as shown in Examples 1-4 for details. BRIEF DESCRIPTION OF THE DRAWINGS

[0055] Figure 1 is the concentration-time curve of abiraterone in plasma after the dog orally took the self-made soft capsule (T) on an empty stomach in Example 1;

[0056] Figure 2 This is the concentration-time curve of abiraterone in plasma after the dog orally took the original drug Zytiga tablets and soft capsules (R1st) on an empty stomach in Example 1;

[0057] Figure 3 This is the concentration-time curve of abiraterone in plasma after the dog orally took the original drug Zytiga tablets and soft capsules (R2nd) on an empty stomach in Example 1;

[0058] Figure 4 is the mean concentration-time curve (Mean+SD) of abiraterone in plasma of 6 dogs after oral administration of different preparations on an empty stomach in Example 1;

[0059] Figure 5 This is the average concentration-time curve (Mean+SD) of abiraterone in plasma of 8 dogs after oral administration of the self-prepared preparation on an empty stomach or after a meal in Example 1. DETAILED DESCRIPTION

[0060] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention, showing that the described embodiments are only part of the embodiments of the present invention, rather than all the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative work are within the scope of protection of the present invention.

[0061] Example 1

[0062] This embodiment provides an abiraterone acetate soft capsule (batch: 1000 capsules), the contents of which include the following components:

[0063]

[0064]

[0065] The above pharmaceutical composition is filled into a soft capsule shell as the content. The components of the soft capsule shell include: gelatin, water, glycerin, sorbitol sorbitan solution MDF85, and the ratio of each component is 1:0.74:0.35:0.35.

[0066] The preparation method is provided as follows:

[0067] 1) Gelatinization: Add the prescribed amount of glycerin, sorbitol, sorbitan and water into a gelatinization barrel, start stirring, seal and heat to 75°C, after the materials are evenly mixed, add the prescribed amount of gelatin, and simultaneously evacuate to -0.05 to -0.06MPa, maintain negative pressure stirring for 25-35 minutes, open the top respirator until the vacuum disappears, keep warm at 55-60°C for degassing, and set aside; 2) Preparation of contents: Dissolve abiraterone acetate in a mixed solution of caprylic and capric mono- and diglycerides, Tween 80, Span 80 and antioxidants heated to 50°C, stir evenly, and set aside; 3) Pilling: Use a soft capsule machine for pilling; 4) Drying.

[0068] Example 2

[0069] This embodiment provides an abiraterone acetate soft capsule (batch: 1000 capsules), the contents of which include the following components:

[0070]

[0071] The above pharmaceutical composition is filled into a soft capsule shell as the content. The components of the soft capsule shell include: gelatin, water, glycerin, sorbitol sorbitan solution MDF85, and the ratio of each component is 1:0.74:0.35:0.35.

[0072] The preparation method is provided as follows:

[0073] 1) Gelatinization: Add the prescribed amount of glycerin, sorbitol, sorbitan and water into a gelatinization barrel, start stirring, seal and heat to 75°C, after the materials are evenly mixed, add the prescribed amount of gelatin, and simultaneously evacuate to -0.05 to -0.06MPa, maintain negative pressure stirring for 25-35 minutes, open the top respirator until the vacuum disappears, keep warm at 55-60°C for degassing, and set aside; 2) Preparation of contents: Dissolve abiraterone acetate in a mixed solution of caprylic and capric mono- and diglycerides, Tween 80, Span 80 and antioxidants heated to 50°C, stir evenly, and set aside; 3) Pilling: Use a soft capsule machine for pilling; 4) Drying.

[0074] Example 3

[0075] This embodiment provides an abiraterone acetate soft capsule (batch: 1000 capsules), the contents of which include the following components:

[0076]

[0077]

[0078] The above pharmaceutical composition is filled into a soft capsule shell as the content. The components of the soft capsule shell include: gelatin, water, glycerin, sorbitol sorbitan solution MDF85, and the ratio of each component is 1:0.74:0.35:0.35.

[0079] The preparation method is provided as follows:

[0080] 1) Gelatinization: Add the prescribed amount of glycerin, sorbitol, sorbitan and water into a gelatinization barrel, start stirring, seal and heat to 75°C, after the materials are evenly mixed, add the prescribed amount of gelatin, and simultaneously evacuate to -0.05 to -0.06MPa, maintain negative pressure stirring for 25-35 minutes, open the top respirator until the vacuum disappears, keep warm at 55-60°C for degassing, and set aside; 2) Preparation of contents: Dissolve abiraterone acetate in a mixed solution of caprylic and capric mono- and diglycerides, Tween 80, Span 80 and antioxidants heated to 50°C, stir evenly, and set aside; 3) Pilling: Use a soft capsule machine for pilling; 4) Drying.

[0081] Example 4

[0082] This embodiment provides an abiraterone acetate soft capsule (batch: 1000 capsules), the contents of which include the following components:

[0083]

[0084] The above pharmaceutical composition is filled into a soft capsule shell as the content. The components of the soft capsule shell include: gelatin, water, glycerin, sorbitol sorbitan solution MDF85, and the ratio of each component is 1:0.74:0.35:0.35.

[0085] The preparation method is provided as follows:

[0086] 1) Gelatinization: Add the prescribed amount of glycerin, sorbitol, sorbitan and water into a gelatinization barrel, start stirring, seal and heat to 75°C, after the materials are evenly mixed, add the prescribed amount of gelatin, and simultaneously evacuate to -0.05 to -0.06MPa, maintain negative pressure stirring for 25-35 minutes, open the top respirator until the vacuum disappears, keep warm at 55-60°C for degassing, and set aside; 2) Preparation of contents: Dissolve abiraterone acetate in a mixed solution of caprylic and capric mono- and diglycerides, Tween 80, Span 80 and antioxidants heated to 50°C, stir evenly, and set aside; 3) Pilling: Use a soft capsule machine for pilling; 4) Drying.

[0087] Comparative Example 1

[0088] Referring to Example 1 of patent CN110538150A, a prescription process of Comparative Example 1 is provided, and its contents include the following components:

[0089]

[0090] This comparative example 1 further provides an abiraterone acetate capsule, which uses the above-mentioned pharmaceutical composition as the content, and the content is filled in the capsule shell.

[0091] The preparation method is provided as follows:

[0092] Take hydrogenated castor oil / castor oil, monoolein, and polyoxyethylene castor oil EL35, then add abiraterone acetate, and then ultrasonicate for 10 minutes under light-proof conditions. Use mechanical stirring (300 rpm) and stir for 20 minutes to fully dissolve it. Then add propylene glycol and ethanol to form a transparent and uniform self-emulsifying solution, fill it into soft capsules or seal it in hard capsules under nitrogen protection for storage.

[0093] Example 5

[0094] This test example provides dissolution tests of the abiraterone acetate soft capsules and the original drug Zytiga tablets provided in Examples 1-4 and Comparative Example 1.

[0095] Test method: According to (the second method of Part IV of the 2015 edition of the Chinese Pharmacopoeia, 0931), the dissolution of abiraterone acetate soft capsules was tested. At 37°C, 900ml of pH 4.5-0.25% SDS medium and 50 rpm, the dissolution of abiraterone acetate soft capsules (prepared in Examples 1 and 2) and the original drug Zytiga tablets were tested.

[0096] Among them, pH 4.5-0.25% SDS medium: weigh 6.78g of anhydrous sodium dihydrogen phosphate, add 1000ml of water to dissolve, adjust the pH value to 4.5 with 5mol / L sodium hydroxide solution to obtain a buffer solution, weigh 2.5g of sodium dodecyl sulfate, add it to the buffer solution, and dissolve it to obtain.

[0097] The specific method is as follows:

[0098]

[0099]

[0100] Table 1-1. Dissolution of Abiraterone Acetate Soft Capsules and Zytiga Tablets (%)

[0101] Sampling points / min Zytiga Example 1 Example 2 Example 3 Example 4 Comparative Example 1 5 13.77 69.01 68.61 71.51 72.01 73 10 28.03 93.51 92.01 93.15 94.51 93 15 41.78 95.83 94.91 96.41 96.83 96 20 57.99 97.62 96.72 97.52 98.05 98 30 79.15 98.70 99.10 99.60 98.20 99 45 92.88 98.52 99.52 98.41 99.12 98

[0102] The comparison results in Table 1-1 show that: ① The abiraterone acetate soft capsules (Examples 1, 2, 3, and 4) of the present invention are basically completely dissolved in the medium in 15 minutes (Note: the dissolution standard of the original drug Zytiga: 45 minutes must not be less than 85.0% of the labeled amount), while the dissolution of the marketed abiraterone acetate tablet Zytiga still cannot reach 85.0% at 30 minutes; ② The dissolution of the abiraterone acetate soft capsules (Examples 1, 2, 3, and 4) of the present invention is not significantly different from that of Comparative Example 1. Therefore, the abiraterone acetate capsules of the present invention can effectively improve the dissolution of abiraterone and significantly improve the oral bioavailability of abiraterone acetate.

[0103] Example 6

[0104] This test example provides stability (long-term test and accelerated test) tests of the abiraterone acetate soft capsules provided in Examples 1-4. The test results are detailed in Tables 2-1 and 2-2.

[0105] Table 2-1. Stability of samples under long-term test (25℃±2℃ / 60%RH±5%RH)

[0106]

[0107] Note: “-” represents: clear solution, no drug precipitation;

[0108] “+” represents: clear solution with a small amount of drug precipitated.

[0109] Table 2-2. Stability of samples under accelerated test (40℃±2℃ / 75%RH±5%RH)

[0110]

[0111]

[0112] Note: “ND” stands for not detected; “NA” stands for not detected.

[0113] The comparison results in Table 2-1 show that the properties of the contents of the abiraterone acetate soft capsules (Examples 1, 2, 3, and 4) of the present invention did not change significantly within a long-term of 9 months, and there was no significant difference in Comparative Example 1 within a long-term of 6 months, but a small amount of drug precipitation occurred after a long-term of 9 months. The reason is that the content prescription of Comparative Example 1 contains propylene glycol and ethanol. As the storage time increases, propylene glycol and ethanol may penetrate the capsule shell and volatilize, reducing the solubility of the drug and causing precipitation of abiraterone acetate.

[0114] The comparison results in Table 2-2 show that: ① The total impurities of the abiraterone acetate soft capsules (Examples 1, 2, 3, and 4) of the present invention have an increasing trend within the accelerated 6 months and meet the product quality requirements (Note: the total impurities in the quality standard of the original drug Zytiga shall not exceed 2.0%); ② The growth rate of the total impurities of the abiraterone acetate soft capsules (Examples 1, 2, 3, and 4) of the present invention within the accelerated 6 months is significantly less than that of the comparative example 1

[0115] Example 7

[0116] This test example provides a self-emulsification ability and stability test of the abiraterone acetate soft capsules provided in Examples 1-4.

[0117] The abiraterone acetate soft capsules prepared in Example 1-4 were added to purified water, and the appearance and stability of the solution at room temperature were observed after slight shaking. See Table 3-1 for details.

[0118] Table 3-1. Sample self-emulsification ability and stability results

[0119]

[0120] Example 8

[0121] This test example provides a pharmacokinetic test of Example 1 and the original research drug Zytiga of abiraterone acetate.

[0122] Experimental design: Due to the large in vivo variability of the original drug Zytiga (abiraterone acetate tablets), this pharmacokinetic study used a three-period crossover test with 6 dogs. The dogs were orally administered with 1 abiraterone acetate soft capsule (specification: 40 mg) and 2 original drug Zytiga (specification: 250 mg, 2 tablets each time) on an empty stomach. Blood samples were collected to determine the concentration of abiraterone in plasma and calculate the main pharmacokinetic parameters. See Table 4-1 for details.

[0123] Test subjects: 6 healthy beagle dogs were randomly divided into 3 groups, 2 in each group, and a 3-cycle crossover test was conducted. During the test, the dogs were free to drink water, and they were fasted for more than 12 hours before each cycle of administration. The preparations were taken with 20 ml of water during administration, and they were fed 6 hours after administration. The washout period between cycles was 7 days.

[0124] Table 4-1 Group design for comparative pharmacokinetic studies

[0125]

[0126] Note: T: Abiraterone acetate soft capsule, 1 capsule / dog, i.e. 40 mg / dog;

[0127] R: Abiraterone acetate tablets, 2 tablets / dog, i.e. 500 mg / dog.

[0128] Table 4-2 Pharmacokinetic parameters of original drug Zytiga 500mg vs. Abiraterone acetate soft capsule 40mg (fasting test)

[0129]

[0130]

[0131] Note: Tmax is the peak time, Cmax is the maximum blood drug concentration (peak concentration), and AUClast is the AUC (area under the drug-time curve) from the start of drug administration to the last point;

[0132] As shown in Table 4-2, the oral bioavailability (AUClast) of beagle dogs taking one abiraterone acetate soft capsule (specification 40 mg) on ​​an empty stomach was 101.9% and 95.3% respectively compared with the original drug Zytiga (R1st) and the original drug Zytiga (R2nd). This shows that the oral bioavailability of the abiraterone acetate soft capsule of the present invention is increased to 12.5 times compared with the original drug Zytiga (specification 250 mg), and the variability of AUClast is smaller.

[0133] Depend on Figure 1 , Figure 2 and Figure 3 It can be seen that the drug-time curves of abiraterone acetate soft capsules in different individuals are close to each other, while the drug-time curves of the original drug Zytiga in different individuals are relatively discrete. The reason may be that the soft capsule dosage form does not need to go through the dissolution step of the original drug Zytiga in the digestive tract, which directly affects the absorption of the drug, thereby improving the bioavailability and reducing individual differences.

[0134] In summary, ① after taking abiraterone acetate soft capsules orally on an empty stomach, dogs skipped the dissolution step of the original drug Zytiga in the digestive tract, and the oral bioavailability (AUClast) of abiraterone acetate soft capsules was 12.5 times that of the original drug Zytiga, and abiraterone acetate soft capsules could obtain more consistent T between individuals. max , C max and AUC, which is beneficial to the implementation of clinical treatment and the control of safety risks.

[0135] Example 9

[0136] This test example provides a test on the effect of food on the absorption of Example 1.

[0137] Experimental design: A two-period crossover study was conducted on 8 dogs. Abiraterone acetate soft capsules were taken orally on an empty stomach and after meals. Blood samples were collected to determine the concentration of abiraterone in plasma and calculate the main pharmacokinetic parameters. See Table 5-1 for details.

[0138] Test subjects: 8 healthy beagle dogs were randomly divided into 2 groups, 4 in each group, and a 3-cycle crossover test was conducted. The dogs were allowed to drink water freely during the test. The drugs were administered on an empty stomach and fasted for more than 12 hours before administration. The drugs were taken with 20 ml of water and fed 6 hours after administration. The drugs were administered after meals and fed by gastric tube 30 minutes before administration. The washout period between cycles was 7 days.

[0139] Table 5-1 Group design of food effect study

[0140]

[0141] Note: T: Abiraterone acetate soft capsule, 1 capsule / dog, i.e. 40 mg / dog.

[0142] Table 5-2 Pharmacokinetic parameters of abiraterone in plasma after oral administration of abiraterone acetate soft capsules on an empty stomach in dogs

[0143]

[0144] Table 5-3 Pharmacokinetic parameters of abiraterone in plasma after oral administration of abiraterone acetate soft capsules in dogs

[0145]

[0146] *Relative bioavailability of each individual F = (abiraterone acetate soft capsule post-meal AUC 0-t / Fasting AUC 0-t )*100%

[0147] As shown in Table 5-2 and Table 5-3, compared with oral administration of Abiraterone Acetate Soft Capsules on an empty stomach, the relative bioavailability of Abiraterone Acetate Soft Capsules in dogs 30 minutes after a meal was 79.19% (44.45% to 106.80%). The paired t-test results of the main pharmacokinetic parameters after natural logarithm transformation are shown in Table 5-4.

[0148] Table 5-4 Paired t-test results of the main pharmacokinetic parameters of abiraterone in the plasma of dogs after oral administration of abiraterone acetate soft capsules on an empty stomach or after meals

[0149]

[0150] As shown in Table 5-4, compared with oral administration of abiraterone acetate soft capsules on an empty stomach, the difference in Cmax after oral administration of soft capsules to dogs after meals was significant (P<0.01), while the differences in AUC0-t and AUCinf were not statistically significant.

[0151] Literature reports that the exposure of abiraterone after a high-fat meal with the original drug Zytiga can reach 10 times the exposure on a fasting stomach. In this study, the exposure of abiraterone did not increase after the dogs took abiraterone acetate soft capsules orally on an empty stomach or after a meal. The reason may be that abiraterone acetate soft capsules do not need to go through the dissolution step of the original drug Zytiga in the digestive tract, and no longer need to rely on the fat in the food to achieve drug dissolution to achieve a higher exposure. The presence of food can no longer increase its absorption. The relative bioavailability of abiraterone administered after a meal is slightly lower than that of an empty stomach. The reason may be that food promotes peristalsis and emptying of the digestive tract, shortening the drug's residence time in the main absorption site.

[0152] In summary, compared with fasting, the exposure of dogs to abiraterone was slightly reduced after oral administration of the self-developed preparation, and there was no significant increase in abiraterone exposure as seen with the original drug Zytiga after meal administration. Therefore, abiraterone acetate soft capsules can reduce the safety risks associated with abiraterone exposure caused by diet.

[0153] Although the present invention has been described in detail above by general description, specific implementation methods and experiments, it is obvious to those skilled in the art that some modifications can be made based on the present invention. Therefore, these modifications and improvements made without departing from the spirit of the present invention all fall within the scope of protection claimed by the present invention.

Claims

1. An abiraterone acetate soft capsule, comprising contents and a capsule shell, characterized in that: The content comprises active ingredients such as abiraterone acetate, caprylic and capric mono- and di-glycerides, Tween 80, Span 80 and butylated hydroxyanisole.

2. The abiraterone acetate soft capsule according to claim 1, characterized in that: Based on the total volume of the contents, the concentration of abiraterone acetate is between 60-100 mg / ml; and / or The mass of the abiraterone acetate accounts for 6-10% of the total mass of the drug content.

3. The abiraterone acetate soft capsule according to claim 1, characterized in that: The mass of the caprylic and capric mono- and di-glycerides accounts for 60-77% of the total mass of the drug content.

4. The abiraterone acetate soft capsule according to claim 1, characterized in that: The mass of the abiraterone acetate accounts for 6-10% of the total mass of the drug content, and the mass of the caprylic and capric mono- and di-glycerides accounts for 60-77% of the total mass of the drug content.

5. The abiraterone acetate soft capsule according to claim 1, characterized in that: The mass of Tween 80 accounts for 6-15% of the total mass of the drug content.

6. The abiraterone acetate soft capsule according to claim 1, characterized in that: The mass of the Span 80 accounts for 7-19% of the total mass of the drug content.

7. The abiraterone acetate soft capsule according to claim 1, characterized in that: The mass of the abiraterone acetate accounts for 6-10% of the total mass of the drug contents, the mass of the caprylic and capric mono- and di-glycerides accounts for 60-77% of the total mass of the drug contents, the mass of the Tween 80 accounts for 6-15% of the total mass of the drug contents, and the mass of the Span 80 accounts for 7-19% of the total mass of the drug contents.

8. The abiraterone acetate soft capsule according to claim 1, characterized in that: The mass of the butylated hydroxyanisole accounts for 0.01%-0.1% of the total mass of the drug content.

9. The abiraterone acetate soft capsule according to claim 1, characterized in that: The mass of the abiraterone acetate accounts for 6-10% of the total mass of the drug contents, the mass of the caprylic capric mono- and diglycerides accounts for 60-77% of the total mass of the drug contents, the mass of the Tween 80 accounts for 6-15% of the total mass of the drug contents, the mass of the Span 80 accounts for 7-19% of the total mass of the drug contents, and the mass of the butylated hydroxyanisole accounts for 0.01%-0.1% of the total mass of the drug contents.

10. The abiraterone acetate soft capsule according to claim 1, characterized in that: The capsule shell is made of soft capsule material, and its composition includes: gelatin, water, glycerin, sorbitol sorbitan solution MDF85, and the proportion of each component is 1:0.74:0.35:0.

35.

11. The abiraterone acetate soft capsule according to claim 1, characterized in that: The contents include: the mass of abiraterone acetate accounts for 6-10% of the total mass of the drug contents, the mass of caprylic and capric mono- and diglycerides accounts for 60-77% of the total mass of the drug contents, the mass of Tween 80 accounts for 6-15% of the total mass of the drug contents, the mass of Span 80 accounts for 7-19% of the total mass of the drug contents, and the mass of butylated hydroxyanisole accounts for 0.01%-0.1% of the total mass of the drug contents; the capsule shell is made of soft capsule material, and its composition includes: gelatin, water, glycerin, sorbitol sorbitan solution (MDF85), and the ratio of each component is 1:0.74:0.35:0.

35.

12. A method for preparing the abiraterone acetate soft capsule according to claim 1-11, the method comprising: 1) Gelatinization: Add the prescribed amount of glycerol, sorbitol, sorbitan and water into a gelatinization barrel, start stirring, wait until the temperature in the barrel rises to 75-80°C, and after the materials are evenly mixed, add the prescribed amount of gelatin, and simultaneously evacuate to -0.05 to -0.06 MPa, maintain negative pressure stirring for 25-35 minutes, open the top respirator until the vacuum disappears, keep warm at 55-60°C for degassing, and set aside; 2) Preparation of contents: Dissolve abiraterone acetate in a mixed solution of caprylic and capric mono- and diglycerides, Tween 80, Span 80 and an antioxidant heated to 50°C, stir evenly, and set aside; 3) Pilling: Use a soft capsule machine for pilling; 4) Drying.

13. An abiraterone acetate soft capsule as described in claims 1-11, calculated as abiraterone acetate, a single oral dose of 36-60 mg, preferably, a single oral dose of 40 mg.

14. Use of the abiraterone acetate soft capsule according to claim 1-11 in the preparation of a pharmaceutical preparation; Preferably, the use in preparing a pharmaceutical preparation for treating prostate cancer; More preferably, the prostate cancer is one or both of metastatic castration-resistant prostate cancer and metastatic high-risk castration-sensitive prostate cancer.

Citation Information

Patent Citations

  • A liquid capsule containing abiraterone acetate

    CN102961358B

  • Abiraterone acetate formulation and methods of use

    CN106687112A

  • Complexes of abiraterone acetate, process for the preparation thereof and pharmaceutical compositions containing them

    CN107278152A

  • Drug composition containing abiraterone acetate and preparation method and application of drug composition

    CN110538150A